Europe • Euronext Milan • BIT:1SAN • FR0000120578
The current stock price of 1SAN.MI is 79.21 EUR. In the past month the price decreased by -8.24%. In the past year, price decreased by -15.95%.
ChartMill assigns a fundamental rating of 4 / 10 to 1SAN.MI. While 1SAN.MI has a great profitability rating, there are quite some concerns on its financial health.
Over the last trailing twelve months 1SAN.MI reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS decreased by -5.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
29 analysts have analysed 1SAN.MI and the average price target is 101.29 EUR. This implies a price increase of 27.88% is expected in the next year compared to the current price of 79.21.
For the next year, analysts expect an EPS growth of 2.24% and a revenue growth -0.09% for 1SAN.MI
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 84587
Phone: 33153774000
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
The current stock price of 1SAN.MI is 79.21 EUR. The price increased by 2.82% in the last trading session.
SANOFI (1SAN.MI) has a dividend yield of 5.35%. The yearly dividend amount is currently 3.79.
1SAN.MI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
The PE ratio for SANOFI (1SAN.MI) is 10.42. This is based on the reported non-GAAP earnings per share of 7.6 and the current share price of 79.21 EUR.
SANOFI (1SAN.MI) will report earnings on 2026-04-23.